Tübingen: Student assistant (f/m/d) as developmental support

Faculty of Medicine, Department of Peptide-based Immunotherapy, index number 6790

Full-/Part-time
by arrangement

Limited:
min. 6 months*

Start of work:
01.12.2026

Application deadline:
07.11.2025

Tasks

• Working with HPC environments and nf-core pipelines
• Aid the Mass Spectrometry team with running and maintaining in-house pipelines
• Managing and extending mass spectrometry pipelines (incl. inventorization and transferring) that we have available in-house and are / become available on PRIDE 
• Developing new tools and apps to streamline immunopeptidomics analysis

Profile

• Programming experience in Python and/or R
• Optional: Experience with Docker or Singularity and nextflow pipelines
• Fluent English language skills
• Flexibility in terms of time

Benefits

• Work in the diverse environment of a modern university hospital, which, in addition to patient care, also focuses on medical research and teaching 
• Future-proof job and location, as well as attractive compensation including a company pension plan (VBL), with the greatest possible flexibility in working hours 
• Subsidies for public transport tickets and attractive discounts on our employee service platforms 
• Structured onboarding phase, hospital-owned academy for developing professional, social, and methodological skills 
• Preventive health care through a wide range of sports activities

About us

The Faculty of Medicine is one of the four founding faculties of the Eberhard Karls University of Tübingen. With its non-clinical facilities as well as its research and teaching area corresponding to the organisational units of the University Hospital, it is one of the largest medical training and research institutions in Baden-Württemberg.

Department of Peptide-based Immunotherapy

The Department of Peptide-based Immunotherapy, led by Prof. Dr. med. Juliane Walz at the Institute of Immunology of the University of Tübingen and University Hospital Tübingen is focused on developing peptide-based immunotherapies for tumor and infectious diseases, particularly in vaccine development. This includes the identification and characterization of tumor-associated and virus-derived antigens, as well as their translation into clinical trials.